Bio Park-Jerusalem’s Largest Biopharma and MedTech Park is Open for Business!
Bio Park’s vision is to create the largest industrial bio-park (Existing: 40K sqm and planned 300 K sqm) with a human-centric village, offering: Offices, labs,
SpliSense Granted FDA & EMA Orphan Drug Designation to SPL84-23-1 for Cystic Fibrosis Treatment
Jerusalem-based Splisense, a biopharmaceutical company developing transformative mRNA altering therapies for cystic fibrosis (CF) and other pulmonary diseases, has been granted orphan drug designation (ODD)
Cell Cure Neurosciences enters exclusive worldwide collaboration with Genentech (Roche Group) for Ocular Disorders
Lineage Cell Therapeutics, Inc. (NYSE and TASE: LCTX) and its subsidiary Cell Cure Neurosciences, Ltd, recently entered into an exclusive worldwide collaboration and license agreement
Oramed Pharmaceuticals Lands Vietnamese Distribution Agreement, Key European Patent Grant, & Oral Vaccine to be developed in Mexico
Distribution Agreement with Vietnam Jerusalem’s Oramed Pharmaceuticals (ORMP.O) Oravax Medical unit signed a deal with Vietnam’s Tan Thanh Holdings for the pre-order of 10 million
BrainsWay Presents Deep TMS™ Trial Results for Reduction of Heavy Drinking
BrainsWay Ltd. (NASDAQ & TASE: BWAY), a global leader in the advanced non-invasive treatment for mental health disorders, published in the scientific journal Biological Psychiatry
Accellix Raises $10 Million for Cell Phenotyping for Cell Therapy
Accellix Inc., which provides quick and accurate flow cytometry results in a compact and easy-to-use platform designed for use by cell therapy companies on the
OmnySense’s Smart-Thermometer Also Monitors Lung Sounds
OmnySense Ltd. started a clinical trial at Wolfson Medical Center in December 2021 to evaluate the use of OmnySense technology to monitor and analyze respiratory
Olive Diagnostics Health Early Warning Urinalysis System Targets European Elder Care Facilities
Olive Diagnostics, an eHealthVentures portfolio company, is on the cusp of receiving regulatory approval and beginning the product launch of their game-changing technology, the world’s
Mirror Biologics, Inc. Closes a $14 Million Financing Round
Mirror Biologics, Inc., a clinical-stage immunotherapy company specializing in the development, manufacturing, commercialization, and clinical translation of next-generation therapeutic in-situ vaccines for cancer and infectious
